Research Analysts Issue Forecasts for CervoMed Q1 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Equities researchers at Roth Capital lifted their Q1 2025 earnings per share estimates for shares of CervoMed in a research note issued to investors on Tuesday, December 10th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will post earnings per share of ($0.52) for the quarter, up from their previous estimate of ($0.53). Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.76) per share. Roth Capital also issued estimates for CervoMed’s Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.27) EPS and FY2025 earnings at ($1.57) EPS.

A number of other brokerages also recently commented on CRVO. Chardan Capital reissued a “neutral” rating on shares of CervoMed in a research note on Wednesday. HC Wainwright began coverage on CervoMed in a report on Thursday, December 5th. They issued a “buy” rating and a $42.00 price target for the company. Roth Mkm initiated coverage on CervoMed in a research note on Friday, December 6th. They set a “buy” rating and a $45.00 price objective on the stock. Morgan Stanley reaffirmed an “underweight” rating on shares of CervoMed in a research report on Wednesday. Finally, Canaccord Genuity Group dropped their target price on CervoMed from $65.00 to $12.00 and set a “buy” rating on the stock in a report on Wednesday. One analyst has rated the stock with a sell rating, three have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $42.00.

CervoMed Stock Performance

NASDAQ CRVO opened at $1.90 on Friday. CervoMed has a one year low of $1.81 and a one year high of $26.38. The company’s 50 day moving average price is $11.28 and its 200 day moving average price is $14.67.

CervoMed (NASDAQ:CRVO) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.14). CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%. The firm had revenue of $1.94 million during the quarter, compared to analyst estimates of $1.75 million.

Institutional Investors Weigh In On CervoMed

Hedge funds have recently bought and sold shares of the business. FMR LLC purchased a new position in shares of CervoMed during the 3rd quarter valued at approximately $56,000. Fred Alger Management LLC acquired a new stake in CervoMed in the second quarter valued at $60,000. Rhumbline Advisers acquired a new stake in CervoMed in the second quarter valued at $96,000. Barclays PLC boosted its stake in CervoMed by 323.6% during the 3rd quarter. Barclays PLC now owns 7,748 shares of the company’s stock valued at $113,000 after acquiring an additional 5,919 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in CervoMed during the 2nd quarter worth $236,000. Institutional investors and hedge funds own 25.15% of the company’s stock.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.